Enterprise Value
-18.51M
Cash
47.95M
Avg Qtr Burn
-3.514M
Short % of Float
2.08%
Insider Ownership
17.47%
Institutional Own.
24.52%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LP-100 (Irofulven) Details Cancer, Castration-resistant prostate cancer | Phase 2 Update | |
LP-300 Details Non-small cell lung carcinoma, Cancer | Phase 2 Update | |
LP-284 Details Cancer, Non-Hodgkin lymphoma, High-grade Glioma
, Mantle cell lymphoma | Phase 1 Data readout | |
LP-184 Details Cancer, Solid tumor/s, Central nervous system illness | Phase 1a Data readout |